BWBen Wu

Ben Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ben Wu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Guocheng Wang

    Research Center for Human Tissues & Organs Degeneration Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen China

    3 shared publications
  • Junkang Chen

    Research Center for Human Tissues & Organs Degeneration Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen China

    2 shared publications
  • Changshun Ruan

    Research Center for Human Tissue and Organ Degeneration, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China

    1 shared publication
  • Emerson Coy

    NanoBioMedical Centre, Adam Mickiewicz University, 3, Wszechnicy Piastowskiej Str., 61-614 Poznan, Poland

    1 shared publication
  • Enrico Marsili

    Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute University of Nottingham Ningbo Ningbo China

    1 shared publication
  • Feng‐Liang Liu

    Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province KIZ‐CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases Center for Biosafety Mega‐Science Kunming Institute of Zoology Chinese Academy of Sciences Kunming Yunnan 650223 China

    1 shared publication

Latest Publications

  • Coordination Reprogramming of Fe‐Antibiotic Assemblies Enables Valence‐Gated β‐Lactam Reactivation

    by Zhengjiang Xu, Yuan Zhang, Ben Wu, Junkang Chen, Qingge Fu, Lijing Fang, Jianghong Wu, Changshun Ruan, Haobo Pan, Yan Xia, et al.

    Reactivating legacy antibiotics offers a practical route to combat drug‐resistant infections, but requires delivery systems that coordinate bacterial engagement with pathogen‐triggered drug release. Here, we report DFC, a deferoxamine (DFO)‐reprogrammed Fe‐carbenicillin (Car) coordination nanoassembly that restores the activity of the legacy β‐lactam antibiotic Car against MRSA. DFC was fabricated via DFO‐mediated competitive coordination, transforming homogeneous Fe‐Car networks into heterogeneous Car‐Fe‐DFO structures. Computational modeling and spectroscopic analyses showed stronger Fe 3+ ‐DFO affinity than Fe 3+ ‐Car binding, DFO‐induced redistribution of the Fe‐centered ligand environment, and sharply weakened Fe‐ligand stability after Fe 3+ ‐to‐Fe 2+ conversion. This coordination reprogramming allowed DFC to remain assembled under nonreducing conditions but rapidly disassemble and release Car under reducing conditions or upon exposure to MRSA. DFC enhanced MRSA targeting, biofilm penetration, and intracellular Fe/Car‐associated accumulation, while Fe‐valence‐triggered destabilization promoted Car release, disrupted iron homeostasis, amplified oxidative stress and lipid peroxidation, and damaged the bacterial envelope. Collectively, these synergistic effects re‑established β‐lactam susceptibility, conferred robust antibacterial and anti‑biofilm efficacy, and markedly promoted pathogen clearance as well as tissue repair, as evidenced in both infected wound and osteomyelitis models. This study establishes competitive coordination reprogramming as a chemical strategy for coupling bacterial iron metabolism with antibiotic liberation and resistance reversal.

  • Top Cited Papers
    Open Access

    Unlocking an Efficient SOD‐to‐CAT Catalytic Relay in a MOF Nanozyme via Dopamine‐Driven Interfacial Nanoreconstruction for Osteoarthritis Therapy

    by Zhiqiang Li, Ben Wu, Weihua Li, Enrico Marsili, Kun Tang, Kuoyang Sun, Zhifu Cao, Yupeng Zhang, Hui Huang, Xiaofeng Li, et al.

    Osteoarthritis (OA) is driven by a vicious cycle of inflammation and reactive oxygen species (ROS). While cobalt‐based metal‐organic framework (MOF) nanozymes are potent catalase (CAT) mimics, their therapeutic efficacy is crippled by an inherently weak superoxide dismutase (SOD)‐like activity that prevents full‐chain ROS scavenging. Here, we resolve this imbalance through an innovative “pre‐embedding/activation” strategy. This approach involves pre‐embedding Zn 2+ into a cobalt‐based framework to create a stable yet activatable precursor. The subsequent dopamine (DA)‐driven “activation” then remodels the latent Zn/Co‐N coordination sites, unlocking an efficient SOD‐to‐CAT catalytic relay by synergistically amplifying the SOD‐like activity for seamless elimination of the entire ROS cascade. This powerful scavenging capability restores mitochondrial function and reprograms macrophages toward an anti‐inflammatory M2 phenotype by inhibiting the ROS‐mediated S100A8/NF‐κB signaling axis and its destructive positive feedback loop. The resulting immunomodulation translates to profound therapeutic outcomes in a rat OA model, where it simultaneously promotes chondrocyte anabolism to achieve significant cartilage repair while suppressing peripheral nerve sensitization to provide sustained pain relief. Our work thus establishes nanoscale interfacial reconstruction as a powerful and rational platform for engineering sophisticated catalytic relays within nanozymes for advanced biomedical applications.


  • ZIF‐67‐Derived Antivirus Cobalt Hydroxide LDH Nanosheets Produced through High‐Concentration Cobalt Ion‐Assisted Hydration

    by Ben Wu, Guofang Zhang, Jiawen Ji, Rong‐Hua Luo, Junkang Chen, Feng‐Liang Liu, Emerson Coy, Sergio E. Moya, Qi Li, Xiaoman Suo, et al.

    In this study, a novel strategy is developed for the first time, referred to as high‐concentration cobalt ion‐assisted hydration (HCCAH) utilizing zeolitic imidazolate framework‐67 (ZIF‐67) as a precursor, to produce independent and flat α‐cobalt hydroxide nanosheets (CHN). These nanosheets offer abundant contact sites for binding with virus surface proteins. The formation of CHN involves the in situ transformation from ZIF‐67, due to the matching of the hydrolysis rate of ZIF‐67 and in situ growth rate of cobalt hydroxide orchestrated by high concentration of cobalt ions. Notably, the CHN contains a higher proportion of trivalent cobalt, which is shown to enhance the binding with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Spike protein and induce protein structural denaturation, as demonstrated by molecular dynamics (MD) simulation. Antiviral experiments using pseudovirus and authentic viruses have confirmed the promising antiviral performance of CHN. Furthermore, both in vitro and in vivo experiments have demonstrated the excellent biocompatibility of CHN. This research opens up new possibilities for the application of cobalt hydroxide nanosheets and serves as a valuable reference for the design of antiviral nanomaterials.